Results 61 to 70 of about 65,249 (309)

Real‐world trends in prenatal antirheumatic drug utilization in Ontario, Canada: A cross‐sectional time‐series analysis

Arthritis Care &Research, Accepted Article.
Objectives This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah, Swaleh Hussain, Sara J.T. Guilcher, Lisa M. McCarthy, Dharini Mahendira, Howard Berger, Mina Tadrous   +6 more
wiley   +1 more source

Nanomaterials Upscaling Cell Production and Advancing Exosome-Based Stem Cell Therapies

Frontiers in Nanotechnology, 2021
The COVID-19 pandemic underlined that by investing in both basic and clinical life science research and if there are enough volunteers, it is feasible to have -validated by Phase III clinical trials- vaccines in less than a year.
Athina Samara, Athina Samara, Branson D. Belle   +2 more
doaj   +1 more source

Characteristics of women with nausea and vomiting of pregnancy who chose to continue compassionate use of placebo after a randomised trial

Journal of Obstetrics and Gynaecology, 2013
The placebo effect has not been characterised in pregnant women suffering from nausea and vomiting of pregnancy (NVP). Our aim was to characterise determinants of the placebo effect in women treated with placebo for NVP. We analysed data from a multicentre, double blind randomised controlled trial of Diclectin (delayed release doxylamine and pyridoxine)
I, Matok, J, Umans, M N, Feghali, S, Clark, S, Caritis, M, Miodovnik, G, Hankins, D R, Mattison, H, Nordeng, G, Koren   +9 more
openaire   +2 more sources

Collaborating with transnational families: Learning from the experiences of family caretakers, educators, psychologists, and spiritual leaders in Honduras

American Journal of Community Psychology, EarlyView.
Abstract This manuscript centers on the experiences of caretakers of minors in Honduran transnational families (TNFs) in which one or both parents emigrated, and of the schoolteachers, professional psychologists, and spiritual leaders working with these families.
Marco Gemignani, Yolanda Hernández‐Albújar, Nerea Larrinaga‐Bidegain   +2 more
wiley   +1 more source

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case

Journal of Pharmaceutical Policy and Practice, 2023
Early access programs (EAPs) generally refer to patient access to medicines/indications before marketing authorization, possibly extended to price and reimbursement approval.
Alice Tarantola, Monica Hildegard Otto, Patrizio Armeni, Francesco Costa, Francesco Malandrini, Claudio Jommi   +5 more
doaj   +1 more source

Psychosocial/survivorship issues in breast cancer: are we doing better? [PDF]

, 2014
Modern breast cancer treatment offers many women greater prospects of cure or lengthier, good quality survival than was possible in the past. Advances include improved diagnostic and staging procedures, sophisticated onco-plastic surgery, enhanced ...
Ahles, Fellowes, Fleissig, Hermelink, Janelsins, Jenkins, Mann, McDonald, Mitchell, Mosher, Panjari, Reid-Arndt, Scherling, Shilling, Stojadinovic, Wefel   +15 more
core   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

American Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, Marc Michel, Carlo Visco, Michael Fillitz, George Kannourakis, Maria Bruna Greve, Moritz Kleemiss, Johan Cid, Andrea Patriarca, Laura Pavan, Arbana Dizdari, Nilla Maschio, Antonella Sau, Cinzia Bitetti, Riccardo Mario Colombo, Luigi Curreli, Dorela Lame, Uros Markovic, Fabrizio Pappagallo, Giacinto Luca Pedone, Davide Rapezzi, Vincenzo Sammartano, Nicola Tumedei, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Antonio De Vivo, Francesco Lanza, Fabrizio Vianello, Esther N. Oliva, Catherine Broome, Francesco Passamonti, Ulrich Jaeger, Bernd Jilma, Guillaume Moulis, Wilma Barcellini   +38 more
wiley   +1 more source

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. [PDF]

, 2019
Neoantigen vaccines involving multi-peptides and poly-epitope-encoding RNA or DNA have undergone early phase clinical testing with modest reported antitumor effects [ 1].
Bouvet, Michael, Carter, Corey, Larson, Chris, Morris, John C, Oronsky, Bryan, Reid, Tony R   +5 more
core   +1 more source

Translational and Regulatory Challenges for Exon Skipping Therapies [PDF]

, 2014
Several translational challenges are currently impeding the therapeutic development of antisense-mediated exon skipping approaches for rare diseases. Some of these are inherent to developing therapies for rare diseases, such as small patient numbers and ...
Aartsma-Rus, A, Balabanov, P, Bushby, K, Duchenne Parent Project, European Med Agency, Ferlini, A, Ferrara, Italy, Goemans, N, Groningen, Katholieke Univ Leuven, Leiden Uni Medical Center, Newcastle, Pasmooij, A M G, Vroom, E, Wells, D J   +14 more
core   +2 more sources

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Special article: compassionate use and clinical trial on CAR-T cells

Hematology, Transfusion and Cell Therapy, 2021
There are only two ways for a patient to gain access to treatment with an experimental product, such as CAR-T cells: participate in a clinical trial or receive a product in a compassionate basis. In the first case, the main beneficiary is society itself, which may in turn obtain a new treatment paradigm for a specific disease.
openaire   +3 more sources